Quadrosilan

Synthetic nonsteroidal estrogen

Quadrosilan
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Quadrosilan is a synthetic nonsteroidal estrogen that belongs to the class of organosilicon compounds. It was developed in the 1960s and is known for its unique chemical structure, which includes a siloxane backbone. Quadrosilan was primarily investigated for its potential use in hormone replacement therapy and other estrogen-related treatments.

Chemical Structure

Structural formula of Quadrosilan

Quadrosilan is characterized by its cyclotetrasiloxane ring, which consists of alternating silicon and oxygen atoms. The chemical name of Quadrosilan is 2,6-cis-Diphenylhexamethylcyclotetrasiloxane, indicating the presence of two phenyl groups and six methyl groups attached to the siloxane ring. This unique structure distinguishes it from other estrogens, which typically have a steroid backbone.

Pharmacology

Quadrosilan acts as an estrogen receptor agonist, meaning it binds to and activates estrogen receptors in the body. This action mimics the effects of natural estrogens, leading to various physiological responses. The nonsteroidal nature of Quadrosilan allows it to interact with estrogen receptors without the steroidal structure, potentially offering different pharmacokinetic properties compared to traditional steroidal estrogens.

Medical Uses

Quadrosilan was explored for use in hormone replacement therapy (HRT) for menopausal symptoms, such as hot flashes and osteoporosis. Its ability to bind to estrogen receptors made it a candidate for alleviating symptoms associated with estrogen deficiency. However, it did not gain widespread clinical use, and its development was eventually discontinued.

Safety and Side Effects

As with other estrogens, the use of Quadrosilan could potentially lead to side effects such as nausea, breast tenderness, and an increased risk of thromboembolic events. The safety profile of Quadrosilan was not extensively studied, and its long-term effects remain largely unknown due to its limited use in clinical practice.

Related Compounds

Quadrosilan is part of a broader class of organosilicon compounds that have been investigated for various medical applications. Other nonsteroidal estrogens include diethylstilbestrol and chlorotrianisene, which have different chemical structures but similar estrogenic activities.

Discontinuation

The development of Quadrosilan was halted, and it is no longer marketed or used in clinical settings. The reasons for its discontinuation include the availability of other more effective and better-studied estrogenic compounds.

Related Pages

• Estrogen
• Hormone replacement therapy
• Nonsteroidal estrogen
• Organosilicon chemistry